<DOC>
	<DOCNO>NCT01518101</DOCNO>
	<brief_summary>Dipeptidyl peptidase-4 ( DPP-4 ) inhibitor glucagonlike peptide-1 ( GLP-1 ) mimetics analog , rely gastrointestinal hormone part incretin system treatment T2DM , provide therapeutic alternative common oral antihyperglycemic agent ( eg , sulfonylurea , thiazolidinediones ) . Although GLP-1 analog DPP-4 inhibitor medication effective , difference product , include method administration ( injectable versus oral ) . Previous study show patient prefer additional oral agent injectable agent fear injection desire avoid . Patient preference clinically financially important , long-term implication term patient ' motivation insight disease state treatment , might direct impact patient 's compliance treatment adherence . The aim current study evaluate proportion T2DM patient prefer oral anti-diabetic treatment vildagliptin + metformin versus injectable anti-diabetic treatment liraglutide 4 week treatment medication .</brief_summary>
	<brief_title>Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients type 2 diabetes Metformin monotherapy &gt; 12 week Hemoglobin A1c ( HbA1c ) &gt; 6.5 % &lt; 9.0 % Body mass Index ( BMI ) 1935 ( kg/m² ) acute diseases randomization kidney diseases creatinin &gt; 120 µmol/l , glomerular filtration rate ( GFR ) &lt; 50 ml/min contraindication Gliptins glucagonlikepeptideanalogues accord respective Summary Product Characteristics ( SmPC ) previous use dipeptidyl peptidase4inhibitors GLP1mimetics Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>patient preference</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>liraglutide</keyword>
</DOC>